Assessment of Healthcare Resource Utilization by Anticoagulant Heparinoid Dosage Level in Patients Hospitalized with COVID-19

Keith Robinson, MD1, Laura L. Schott, PhD2, Tom Matthews, MPH3, Manu Tyagi, MBA2, Vivek B. Ajmani, PhD2, Nancy Sacco, PhD3, and Zhun Cao, PhD2

Abstract
The aim was to describe inpatients with COVID-19 empirically prescribed heparinoid anticoagulants and compare resource utilization between prophylactic/low-dose and therapeutic/high-dose groups. Methods: This retrospective observational study used real-world data from 880 US hospitals in the PINC AI™ Healthcare Database during 4/1/2020–11/30/2020. Descriptive analysis was used to characterize patients. Multivariable regression was used to evaluate intensive care unit (ICU) admissions, length of stay (LOS), mortality, and costs by anticoagulation dose group, adjusting for cohort characteristics. Among 122,508 inpatients, 29,225 (23.9%) received therapeutic/high-dose, and 93,283 (76.1%) received prophylactic/low-dose anticoagulation. The high-dose group had more comorbidities and worse laboratory values compared with low-dose. Respectively, ICU admission rates were 36.7% and 19.1% and LOS median (Q1, Q3) was 8 (5, 15) and 5 (3, 9) days. In separate adjusted models, high-dose anticoagulation was associated with a 45% increase in odds of ICU admission, 26% increase in odds of in-hospital mortality, 21% longer average LOS, and 28% greater average total cost compared with low-dose (each \( P < 0.001 \)). Prophylactic/low-dose anticoagulation treatment was associated with decreased healthcare resource utilization (HRU) in hospitalized patients with COVID-19.

Keywords
COVID-19, anticoagulants, healthcare resource utilization, heparins, thrombosis, prophylaxis

Date received: 10 August 2022; revised: 12 October 2022; accepted: 18 October 2022.

Introduction
Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus resulted in a global pandemic, which affected hospitals worldwide. Coagulopathies are common among patients hospitalized with COVID-19 and are associated with more severe disease and mortality.1–4 In one study, estimated prevalence of thrombosis was 22% overall and 43% among patients admitted to intensive care units (ICUs).5

The results of randomized, placebo-controlled trials indicate that anticoagulation decreases coagulopathy risk in the general population of acutely ill hospitalized patients.6–9 Among patients with COVID-19, anticoagulation has been a common management strategy, used in nearly 69% of US hospitalized patients in one early cohort study.10 Studies indicate that timely thromboprophylaxis improves survival and other key clinical outcomes among patients with COVID-19, and therefore thromboprophylaxis is advised clinically and in medical societies’ guidelines, unless patients have contraindications.6,7,9,11–19

However, observational studies and clinical trials have produced mixed evidence as to the best anticoagulant dose level for patients with COVID-19. Some studies support higher-dose
Similar results were reported when comparing dosage only improved survival among patients who were not critically ill.26,27 In contrast, two robust randomized trials of patients hospitalized with COVID-19 indicated therapeutic-dose anticoagulation only improved survival among patients who were not critically ill.28 These discrepant findings may reflect the biological complexity of coagulopathy in COVID-19 infection.29,30 While it seems clear that most patients hospitalized with COVID-19 will benefit from some level of anticoagulation, the optimal dose remains unclear and is the subject of ongoing clinical trials.31

COVID-19 is associated with substantial healthcare resource utilization (HRU) and costs.32–37 In studies of hospitalized patients, ICU utilization ranged from 15% to 52%.33,35,37–39 Among inpatients with COVID-19, increased total cost and length of stay (LOS) are associated with greater comorbidity burden, poorer hematologic biomarkers, worse clinical severity, and certain demographic characteristics.32,35,37,39,40 Before the COVID-19 pandemic, studies in hospital and outpatient settings evaluated the cost-effectiveness and clinical efficacy of various thromboprophylaxis strategies.41–46 However, to our knowledge, no such studies of HRU and costs related to heparinoid anticoagulation dose level have been reported for patients hospitalized with COVID-19.

Using a large US database, this study compared HRU, costs, and mortality adjusting for confounders among inpatients with COVID-19 who received either prophylactic/low-dose or therapeutic/high-dose anticoagulation (heparin and/or enoxaparin). This study used real-world data for patients who sought hospital care, were diagnosed with COVID-19, and were empirically prescribed heparinoid anticoagulants early during the pandemic.

**Methods**

**Data Source and Study Design**

A retrospective cohort study was conducted using data from the Premier PINC AI™ Healthcare Database - Special Release (PHD-SR), which averages more than 8.5 million inpatient and 75 million outpatient encounters per year and captures 20–25% of all US inpatient hospital discharges. The PHD-SR is an extensive hospital-based database containing service and billing information. By means of a unique PHD-SR patient key, patient data can be tracked within a hospital system. 

Between April 1, 2020, and November 30, 2020, 685,853 patients diagnosed at discharge with COVID-19 (ICD-10-CM U07.1) were identified in the PHD-SR. Hospitalized inpatients and hospital-based outpatients (eg, those seen in an emergency department or hospital-based clinic) were evaluated. The index visit was the COVID-19-related hospital inpatient admission or outpatient visit. After excluding patients aged <18 years (n = 33,234) and patients with cardiovascular diagnoses (ie, atrial fibrillation, stroke, pulmonary embolism/deep vein thrombosis, or pulmonary hypertension) or who received anticoagulants (ie, warfarin or the novel oral anticoagulants apixaban, rivaroxaban, dabigatran, or edoxaban) during the 6 months before the index visit (n = 121,662), the initial analytic sample included 530,957 adults. Patients with prior treatment and diagnoses were excluded because the aim was to assess empirical anticoagulant dosing in patients with COVID-19. Eligible adults diagnosed with COVID-19 included 174,422 inpatients and 356,535 outpatients from 880 hospitals. Only inpatients were evaluated for heparinoid anticoagulant dosage.

All data were compliant with the Health Insurance Portability and Accountability Act (HIPAA). Based on US Title 45 Code of Federal Regulations Part 46, institutional review board approval for this study was not required because the study used pre-existing de-identified hospital data that could not be linked to individuals.

Among inpatients, anticoagulant use and dosing strategies were determined based on the maximum dose during days 0–3 of hospital admission. Total daily dose was categorized as prophylactic/low-dose (<160 mg enoxaparin or <15,000 units of heparin) or therapeutic/high-dose (≥160 mg enoxaparin or ≥15,000 units of heparin). Choice of enoxaparin versus heparin and dosage were at the discretion of individual clinicians’ assessment of the patient. To avoid confounding if these therapies were used for other conditions, doses greater than 320 mg enoxaparin or 25,000 units of heparin were excluded. Anticoagulation was not examined among outpatients because intensity of therapy in this population was expected to vary, which could potentially obscure associations with outcomes.

This cross-sectional study compared anticoagulant dose (ie, prophylactic/low-dose vs therapeutic/high-dose) in adult inpatients hospitalized with COVID-19. Primary study outcomes were ICU admission, LOS, total cost, and in-hospital mortality. Secondary outcomes assessed included clinical complications during hospitalization and readmissions within 60 days.

**Patient Demographics and Visit and Clinical Characteristics**

Data collected for all patients included age, primary insurance payer, and self-reported sex, race, and ethnicity. Individual comorbid conditions and overall risk were assessed using the Charlson Comorbidity Index (CCI)47,48 via primary and secondary ICD-10 diagnosis and procedure codes at discharge and 180 days before the index visit. Also ascertained were obesity, dyspnea, hypertension, dyslipidemia, respiratory support therapy, cardiac imaging tests, medications, and laboratory measures during the visit. Visit characteristics included admission point of origin, admission type, and discharge status, which hospitals submitted according to the uniform billing criteria of the Centers for Medicare and Medicaid Services. Hospital characteristics included geographic region.
Laboratory Measures and Medications

Laboratory measures and vital signs were assessed for all patients for whom these were available. (Not all hospitals in the PHD-SR contribute these data, and all tests also were not ordered for all patients.) Laboratory measures included D-dimer, C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), platelets, eosinophil count/percentage, partial pressure of oxygen, fibrinogen, white blood cell differential (WBC), and erythrocyte sedimentation rate. Additional details regarding determination of laboratory measures, such as testing manufacturer and kit used, were not available in the PHD-SR. Because laboratory measures could be assessed multiple times during hospitalization, both initial and final values were evaluated. If only a single measure was reported during the index visit, it was considered the initial exposure point value. Mean heart rate and diastolic and systolic blood pressure were calculated across the visit. Measurements were not corrected or filtered by minimum or maximum values. Medications assessed for use during the

| Number of hospitals | 770 | 664 |
| Age, median (Q1, Q3) | 62 (49, 74) | 65 (54, 76) |
| Female, n (%) | 45,824 (49.1) | 12,494 (42.8) |
| Race, n (%) | | |
| Asian | 2691 (2.9) | 616 (2.1) |
| White | 51,606 (55.3) | 15,751 (53.9) |
| Black | 19,042 (20.4) | 7063 (24.2) |
| Other | 14,358 (15.4) | 4336 (14.8) |
| Unknown | 5586 (6.0) | 1459 (5.0) |
| Ethnicity, n (%) | | |
| Hispanic or Latino | 20,489 (22.0) | 6368 (21.8) |
| Not Hispanic or Latino | 55,123 (59.1) | 17,542 (60.0) |
| Unknown | 17,671 (18.9) | 5315 (18.2) |
| Discharge status, n (%) | | |
| Home | 54,057 (57.9) | 11,991 (41.0) |
| Home health care | 11,039 (11.8) | 3980 (13.6) |
| SNF, ICF, or long-term care | 14,892 (16.0) | 6240 (21.4) |
| Transfer to another acute care hospital, hospice | 2812 (3.0) | 791 (2.7) |
| Died | 8458 (9.1) | 5648 (19.3) |
| Other/Unknown | 2025 (2.2) | 575 (2.0) |
| Comorbid conditions from CCI, n (%) | | |
| Myocardial infarction | 6114 (6.6) | 3171 (10.9) |
| Congestive heart failure | 10,249 (11.0) | 5096 (17.4) |
| Cerebrovascular disease | 4683 (5.0) | 2094 (7.2) |
| Chronic pulmonary disease | 19,043 (20.4) | 6358 (21.8) |
| Diabetes with chronic complications | 13,141 (14.1) | 6986 (23.9) |
| Diabetes without chronic complications | 24,175 (25.9) | 7403 (25.3) |
| Moderate or severe renal disease | 13,761 (14.8) | 8141 (27.9) |
| Any malignancy, including leukemia and lymphoma | 3081 (3.3) | 1053 (3.6) |
| Metastatic solid tumor | 887 (1.0) | 292 (1.0) |
| Other Comorbid conditions, n (%) | | |
| Dyspnea | 1167 (1.3) | 219 (0.7) |
| Hypertension | 58,888 (63.1) | 21,515 (73.6) |
| Dyslipidemia | 36,643 (39.3) | 13,411 (45.9) |
| Obesity | 22,063 (23.7) | 8317 (28.5) |
| Echocardiogram / ultrasonography of the heart, n (%) | 305 (0.3) | 200 (0.7) |
| Computerized tomography angiography of chest, n (%) | 5285 (5.7) | 1784 (6.1) |
| Ultrasoundography of extremity veins, n (%) | 2257 (2.4) | 1513 (5.2) |
| Premier mortality risk score<sup>b</sup> (probability value, reported as 0–100 range), median (Q1, Q3) | 2.99 (1.22, 9.06) | 6.65 (2.31, 28.89) |

<sup>P < 0.001 for all comparisons between anticoagulant dose groups except for ethnicity and computerized tomography angiography of chest, for which P < 0.01. Abbreviations: CCI, Charlson Comorbidity Index; ICF, intermediate nursing facility; SNF, skilled nursing facility.</sup>

<sup>*Clinical characteristics were identified via primary and secondary ICD-10-CM discharge diagnosis, CPT (Current Procedural Terminology), and/or ICD-10-PCS procedure codes; CCI conditions were identified at discharge and 180 days prior to index visit; Other comorbid conditions were identified at discharge. *Mortality risk score was calculated for inpatients not discharged to another acute care facility (ie, for 97% of the sample).
index visit consisted of ACE inhibitors, β-blockers, calcium channel blockers, corticosteroids, hydroxychloroquine, azithromycin, other antibiotics, remdesivir, tocilizumab, other antivirals, other anticoagulants (ie, not enoxaparin or heparin), and bronchodilators.

**HRU, Costs, Complications, and Risk of Mortality**

For inpatients, HRU was assessed by determining index hospital LOS (as submitted by hospitals), index ICU use (≥1 day in intensive or critical care unit, excluding observation/step-down), and all-cause readmissions within 60 days of discharge. Total cost was the sum of all costs incurred during the index visit. Complications included in-hospital acute respiratory failure, acute respiratory distress syndrome, sepsis, pulmonary embolism, venous thromboembolism, and death. Risk of mortality was assessed using the CareScience Risk Assessment Model score49 for inpatients who were not transferred to another acute facility. This score evaluated a patient’s probability of mortality during the index visit.

**Statistical Analyses**

Results are reported as median (Q1, Q3) or n (%), and comparisons were performed using Wilcoxon Rank Sum and Chi-square tests, respectively. Power analysis was conducted prior to the study, and the sample sizes of the cohorts yielded powers of 0.8 or higher to detect differences in primary outcomes. Because of the large sample size, $P < 0.01$ was defined as significant. All analyses were conducted using SAS version 9.4.

Multivariable regression analyses were used to evaluate outcomes among recipients of anticoagulant heparinoids and address the selection bias due to differences in severity of patients between the two cohorts. For LOS and total cost, generalized linear models (GLM) with log link function and either negative binomial or gamma distribution, respectively, were used. GLM regression coefficients were exponentiated, and 95% confidence intervals for the exponentiated coefficients were reported. Logistic regression was used to assess in-hospital mortality and ICU utilization. Potential covariates for the regression models were evaluated for clinical relevance and statistical appropriateness (ie, overall frequency and differences between dose groups). Sensitivity analyses were completed to assess model fit and properties of variables in the model. Final covariates were retained in the models regardless of statistical significance with outcome measure.

Covariates in the final models included patient demographics (ie, age, sex, race, ethnicity, payer), visit characteristics (ie, admission type, point of origin, discharge status), hospital characteristics (ie, bed size, region, teaching status, urban/rural), clinical characteristics (ie, invasive mechanical ventilation, obesity, dyslipidemia, hypertension), individual comorbidities from the CCI (ie, myocardial infarction, congestive heart failure, cerebrovascular disease, dementia, chronic pulmonary disease, diabetes, cancer, renal disease), and concomitant medications. Discharge status (ie, a severity proxy) was not included in the model that assessed in-hospital mortality.

In adjunct analysis, data were examined separately for the full sample of adults with COVID-19 (ie, all inpatients and outpatients) stratified by patients age (ie, 18–49 years vs ≥50 years). This real-world data (see Supplemental Materials and Adjunct Analyses below) reflected an overview of patients hospitalized with COVID-19 early in the pandemic.

**Results**

**Dataset, Visit, and Hospital Characteristics**

A total of 122,508 patients (70.2% of all inpatients) from 776 hospitals met criteria for heparinoid anticoagulant use and were included in analyses, of which 93,283 (76.1%) received prophylactic/low-dose and 29,225 (23.9%) received therapeutic/high-dose anticoagulation (Table 1). The high-dose group was a median of 3 years older and had a 6.3% lower proportion of female patients than the low-dose group. Distribution of Hispanic/Latino ethnicity was similar, but the high-dose group had more Black and fewer White patients than the low-dose group.

Recipients of heparinoid anticoagulants were primarily emergency/urgent admissions (96.8%) from home or a non-healthcare facility (80.7%); a small proportion (18.7%) were transferred from another healthcare facility. (See Appendix Table 1 in Supplemental Materials.) In the low-dose group, a higher proportion of patients was discharged home (with or without home healthcare; 69.7% total), and a lower proportion was transferred or discharged to another healthcare facility (19%), than in the high-dose group (54.6% discharged home; 24.1% discharged to other healthcare facility; $P < 0.001$ for the overall Chi-square).

**Clinical Characteristics**

Comorbidities and respiratory supportive therapies were more frequent and mortality risk was higher in the therapeutic/high-versus the prophylactic/low-dose group. The proportion of patients in the high-dose group with a CCI score ≥5 was 16.9%, versus 9.2% in the low-dose group, whereas a CCI of 0 was noted in 22.7% and 33.3% of patients in these groups, respectively ($P < 0.001$ for the overall Chi-square). Patients in the high-dose group were significantly more likely to have a comorbid diagnosis of moderate or severe renal disease, diabetes with chronic complications, congestive heart failure, or myocardial infarction than in the low-dose group, with between-group differences ranging from 4% to 13%. Patients in the high-dose group also were more likely to have a discharge diagnosis of hypertension, dyslipidemia, or obesity compared with patients in the low-dose group, with between-group differences of 5% to 10%. Mortality risk score was two times higher in the high- versus the low-dose group ($P < 0.001$).

The therapeutic/high-dose group received more treatments and procedures to manage respiratory failure (Figure 1) and more median days of non-invasive mechanical ventilation and
supplemental oxygen use (5 and 3 days, respectively, vs 4 and 2 days in the prophylactic/low-dose group; both \( P < 0.001 \)). Although use was low (<6% overall), echocardiogram, extremity ultrasound, and computerized tomography angiography procedures were more frequent in the high-dose group.

**Laboratory Measures and Medications**

Results of individual laboratory tests were available for 3.2% to 19.4% of patients, depending on the test and the hospital submitting the data. Data completeness was similar between the dose groups. Initial laboratory values were significantly higher in the high- versus low-dose group for D-dimer (difference: 0.5 mcg/ml), CRP (0.3 mg/L), NLR (1.1 units), and WBC (0.9 1000/L), and these differences persisted at final measurement (Table 2). Fibrinogen values exceeded normal in both dose groups and were statistically similar between groups. Despite some statistical differences, the two groups showed no clinically significant differences in blood pressure, heart rate, prothrombin time, or eosinophil percentage.

Concomitant medication use was more frequent in the high-versus low-dose group. Bronchodilators, β-blockers, calcium channel blockers, corticosteroids, and other antibiotic medications were prescribed 9% to 14% more frequently in the high-dose group, while azithromycin, remdesivir, other antiviral medications, and tocilizumab were prescribed 4% to 5% more frequently.

**HRU, Costs, Clinical Complications, and Mortality**

HRU was higher and complications were more frequently identified in the therapeutic/high- versus prophylactic/low-dose group. Median hospital LOS and median ICU LOS each were 3 days longer in the high-dose group (Figure 2), and more than one-third of patients in the high-dose group spent time in the ICU, compared with less than 20% of patients in the low-dose group (Figure 3). Total and ICU costs were nearly two times higher in the high-dose group compared with the low-dose group.

Compared with the prophylactic/low-dose group, the therapeutic/high-dose group had significantly \( (P < 0.001) \) greater frequencies of clinically relevant complications, including acute respiratory failure (60.2% vs 54.9%), sepsis (37.6% vs 26.3%), acute respiratory distress syndrome (11.7% vs 4.7%), venous thromboembolism (9.4% vs 2.5%), and pulmonary embolism (5.5% vs 1.3%). (See Appendix Table 2 in Supplemental Materials.) Inpatient mortality in the high-dose group was double that of the low-dose group. Moreover, among discharged patients, those who had received high-dose anticoagulation were more likely to be readmitted within 60 days.

**Adjusted Analyses**

Multivariable models (Table 3) substantiated our findings of poorer outcomes and greater HRU in the therapeutic/high-versus prophylactic/low-dose group. After adjusting for demographic, visit-related, and clinical factors, high-dose anticoagulation was associated with a 45% increase in odds of ICU utilization and a 26% increase in odds of in-hospital mortality compared to low-dose. After adjusting for covariates, high-dose anticoagulation was associated with 28% higher average total cost and 21% longer average LOS compared to low-dose. (For associations between covariates and outcomes, see Appendix Tables 3–6 in Supplemental Materials.)

**Adjunct Analyses on the Full Sample**

Results of adjunct analyses on the initial sample of more than half a million adults diagnosed with COVID-19 in the PHD were also assessed and stratified by age groups. Among all patients, mean age was 51.4 years (SD: 19.5 years), 47.1% were age 18–49 years, and 52.9% were >50 years. More than half (53.6%) were female, 20.5% were Black, and 23.9% were Hispanic or Latino. Most patients had private insurance (42.6%) and were urgent/emergency admissions (74.3%) from home or a non-healthcare facility (77.3%). (See Appendix Table 7 in Supplemental Materials.) Regional distribution of hospitals generally reflected the PHD-SR (53.5% South, 21.1% Midwest, 14.1% Northeast, and 11.3% West), whereas proportions of patients treated in urban facilities (84.5%) and teaching hospitals (42.9%) reflected early COVID-19 spread in the US.

HRU and costs were evaluated in the full sample. Among all inpatients with COVID-19 (ie, including those not prescribed anticoagulants), mean and median LOS were 8.3 (SD 9.2) days and 5 days, respectively. Median LOS was 2 days longer among inpatients aged ≥50 years versus 18–49 years (6 vs 4 days; \( P < 0.001 \)). (See Appendix Table 8 in Supplemental Materials.) The proportion of inpatients admitted to the ICU was 23.6% overall, 25.2% among inpatients aged ≥50 years, and 17.8% among inpatients 18–49 years (\( P < 0.001 \)), and median ICU LOS was 1 day longer among inpatients ≥50 years versus 18–49 years (5 vs 4 days; \( P < 0.001 \)). Accordingly, median total cost was approximately US $4000 higher and median ICU cost was approximately US $1900 higher among inpatients aged ≥50 years compared with inpatients 18–49 years (both \( P < 0.001 \)). Among all inpatients, median (Q1, Q3) total cost was $11,205 ($5809, $23,446) and ICU cost was $8220 ($2277, $23,017). Among all outpatients, median (Q1, Q3) visit cost was $307 ($64, $651). Among outpatients, per-visit cost was approximately $90 more for individuals aged ≥50 years versus 18–49 years (\( P < 0.001 \)).

Nearly 5% of the approximately half million inpatients and outpatients in this study died at the hospital, and mortality was significantly higher among individuals aged ≥50 years (7.9%) versus 18–49 years (0.6%; \( P < 0.001 \)). Among inpatients, in-hospital mortality was 13.0%. Among discharged inpatients, rates of 60-day readmission were 10.9% among individuals aged ≥50 years and 6.1% among individuals 18–49 years (\( P < 0.001 \)). Overall, the most common clinically relevant complications were acute respiratory failure (17.5%) and sepsis.
To our knowledge, this is the first real-world data study to examine associations between anticoagulant dose, HRU, and costs among patients hospitalized with COVID-19. Among 122,508 patients hospitalized with COVID-19 and prescribed heparinoids, HRU, hospital costs, morbidity, and mortality all were significantly lower with prophylactic/low-dose versus therapeutic/high-dose anticoagulation. After adjusting for multiple demographics, visit-related, and clinical factors, the low-dose anticoagulant group was associated with 21% to 45% lower risk of ICU utilization, inpatient mortality, LOS, and total cost compared with the high-dose group. Thus, despite likely intention of clinicians to treat more rigorously patients with greater comorbidities and disease severity, no

| Laboratory Measure                  | Initial Measurement | Final Measurement |
|-------------------------------------|---------------------|-------------------|
|                                    | Prophylactic/Low Dose | Therapeutic/High Dose | Prophylactic/Low Dose | Therapeutic/High Dose |
| D-Dimer (mcg/ml), median (Q1, Q3)  | 0.9 (0.5, 1.7)      | 1.5 (0.8, 3.5) ‡ | 0.8 (0.5, 1.7)      | 1.5 (0.7, 3.3) ‡ |
| C-reactive protein (mg/L), median (Q1, Q3) | 1.0 (0.4, 2.7) | 1.3 (0.5, 3.6) ‡ | 0.4 (0.1, 1.6) | 0.5 (0.1, 2.3) † |
| Neutrophil to lymphocyte ratio (no. units), median (Q1, Q3) | 5.2 (3.1, 8.9) | 6.3 (3.6, 11.4) ‡ | 4.5 (2.5, 8.4) | 5.6 (2.9, 11.3) ‡ |
| Partial pressure of oxygen (mm Hg), median (Q1, Q3) | 70.0 (58.3, 88.7) | 69.0 (57.0, 87.0) | 74.0 (61.0, 96.7) | 72.0 (59.0, 91.0) † |
| Erythrocyte sedimentation rate (mm/hr), median (Q1, Q3) | 52 (30, 78) | 55 (32, 80) | 52 (30, 81) | 45 (25, 72) † |
| Platelets (10⁹/L), median (Q1, Q3) | 221 (170, 291) | 220 (167, 296) | 262 (192, 354) | 255 (181, 347) ‡ |
| Fibrinogen (mg/dL), median (Q1, Q3) | 576 (453, 706) | 567 (448, 686) | 526 (405, 635) | 507 (387, 638) |
| White blood cell differential (10⁹/L), median (Q1, Q3) | 7.4 (5.3, 10.3) | 8.3 (5.9, 11.9) ‡ | 7.9 (5.7, 10.8) | 9.1 (6.5, 13.0) ‡ |
| Prothrombin time (seconds), median (Q1, Q3) | 13.2 (11.7, 14.2) | 13.7 (12.5, 14.9) ‡ | 13.8 (12.8, 15.1) | 14.4 (13.2, 16.1) ‡ |
| Eosinophil percent (%), median (Q1, Q3) | 0.1 (0.0, 0.8) | 0.1 (0.0, 1.0) ‡ | 1.0 (0.2, 2.0) | 1.0 (0.2, 2.5) ‡ |

† P < 0.001, ‡ P < 0.01 for comparisons between anticoagulant dose groups. Intra-group differences between initial and final laboratory measurements were not statistically tested.

*When laboratory measures were assessed multiple times during hospitalization, initial and final values were evaluated for comparison between dosing groups. If only a single laboratory measure was reported, it was considered the initial exposure point value. Because a limited number of hospitals submit laboratory data, initial measures were available for 3–20% of all patients, depending on the test, and availability was similar across dosing groups. Sample sizes for evaluations of initial and final laboratory measurements ranged from n = 2949 to 19,042 for initial values and n = 1214 to 16,536 for final values in the prophylactic/low-dose group, and from n = 957 to 4958 for initial values and n = 477 to 4453 for final values in the therapeutic/high-dose group. Measures were not corrected or filtered by minimum or maximum values. Additional details regarding determination of laboratory measures, such as testing manufacturer and kit used, were not available in the database.

Figure 1. Respiratory Management by Anticoagulation Dose Group. P < 0.001 for all comparisons.

Table 2. Laboratory Measures by Anticoagulation Dose Group.*
benefit was observed when evaluating associations between higher anticoagulant dose and outcomes among patients hospitalized with COVID-19.

In this study, overall findings on hospital LOS, ICU utilization, and cost were in line with results from studies of patients with COVID-19 in which assessment was not based on anticoagulant dose. Among all inpatients, median LOS was approximately two days shorter than that reported by others, but after examining anticoagulant use, we found that LOS was about 3 days longer among patients receiving high- versus low-dose heparinoids. Total hospitalization costs in this study were similar to others but were significantly higher among recipients of high- versus low-dose anticoagulation. Similarly, overall ICU utilization was in line with that reported in other studies of patients with COVID-19, but was twice as high among patients who received high-versus low-dose anticoagulation, and consistent with another retrospective study reporting a three-fold increase in ICU admission. Variations in HRU and costs across studies probably reflect differences in study time periods, geographic locations, and severity of illness indicators.

Anticoagulant therapy and dosage are some of the many factors associated with mortality among patients hospitalized with COVID-19. Mortality among inpatients with COVID-19 has varied across time and studies, with rates ranging from 7% to 37%. In general, a reduction of in-hospital mortality is found with any anticoagulant regimen compared with no anticoagulation. Additionally, studies have demonstrated reduced mortality for patients receiving anticoagulants prior to hospitalization for COVID-19 or post-discharge. In the current study, mortality was similar overall to that in other general studies of COVID-19, but was noticeably higher among recipients of high-dose anticoagulation. These findings align with results from previous studies of patients with COVID-19 in which standard prophylactic-dose anticoagulation was associated with lower in-hospital mortality, and/or intermediate-to-therapeutic dose treatment was not associated with improved survival.

However, other studies of patients with COVID-19 have reported discrepant associations between anticoagulant dose and mortality among patients receiving high-dose thromboprophylaxis. Some studies have reported higher mortality...
among non-critically ill patients receiving prophylactic- versus therapeutic-dose anticoagulation, but no differential effect of dosage in critically ill patients.\textsuperscript{26,27,30} Our results contrast with studies supporting the use of higher-dose anticoagulation in patients with COVID-19.\textsuperscript{20–23}

In addition to higher HRU during hospitalization, patients with COVID-19 can develop persistent symptoms requiring additional treatment, emergency visits, and readmissions that continue to burden the healthcare system post-discharge.\textsuperscript{38,51,63,64} Further, patients hospitalized with COVID-19 have higher rates of subsequent mortality.\textsuperscript{63,64}

Guidelines from the American Society of Hematology assert that the incremental cost of thromboprophylaxis “is negligible relative to the total costs” of COVID-19 hospitalization.\textsuperscript{53} Experts recommend that hospital clinicians assess venous thromboembolism risk in patients hospitalized with COVID-19 just as they would for other acutely ill patients; as such, high-risk patients should receive anticoagulants, unless contraindicated.\textsuperscript{16,20,22,65,66}

Clinical observations and autopsy studies suggest a complex set of events whereby thrombosis and anticoagulation precede COVID-19 related deaths.\textsuperscript{55,67} Several mechanisms for hypercoagulopathy and thrombosis in COVID-19 patients have been proposed, including endothelial cell injury, increases in circulating plasminogen, cytokine activation, formation of leukocyte-platelet aggregates, acute systemic inflammation, and progressive organ dysfunction.\textsuperscript{2,20,29,66–73} Whether a specific type of anticoagulant is preferable in the management of patients with COVID-19 remains unclear.\textsuperscript{53}

Some limitations of this study, such as reliance upon accurate and complete diagnoses and procedure coding, are inherent to any analysis of an administrative database. Additionally, since patients in the two anticoagulant dose groups were not randomly assigned, there was potential selection bias because patients with more severe cardiovascular symptoms might be more likely to receive therapeutic/high-dose versus prophylactic/low-dose anticoagulation. Although the assessment of the lab measures showed no clinically significant differences in blood pressure, heart rate, fibrinogen, prothrombin time, or eosinophil percentage among non-critically ill patients receiving prophylactic- versus therapeutic-dose anticoagulation, but no differential effect of

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure3}
\caption{Outcomes by Anticoagulation Dose Group. P < 0.001 for all comparisons. Abbreviation: ICU, intensive care unit.}
\end{figure}

\begin{table}[h]
\centering
\begin{tabular}{|l|l|l|}
\hline
Outcome & Estimate\textsuperscript{b} & 95\% Confidence interval \\
\hline
Logistic regression & & \\
ICU Utilization & 1.45 & 1.40, 1.51 \\
In-hospital mortality & 1.26 & 1.20, 1.50 \\
\hline
Generalized linear model (GLM) & & \\
Total index hospitalization cost & 1.28 & 1.26, 1.29 \\
Total index hospitalization & 1.21 & 1.20, 1.22 \\
length of stay & & \\
\hline
\end{tabular}
\caption{Multivariable Regression Analyses\textsuperscript{a} Comparing Therapeutic/High-Dose Versus Prophylactic/Low-Dose Anticoagulation Groups.}
\end{table}

\textsuperscript{a}The following covariates were also included in each model: demographics (ie, age, sex, race, ethnicity, primary insurance payer), visit characteristics (ie, admission type, point of origin, discharge status), hospital characteristics (ie, bed size, geographic region, teaching status, and urban/rural population served), clinical characteristics (ie, invasive mechanical ventilation, obesity, dyslipidemia, hypertension), individual comorbidities from the Charlson Comorbidity Index (ie, myocardial infarction, congestive heart failure, cerebrovascular disease, dementia, chronic pulmonary disease, any diabetes [diabetes with chronic complication / diabetes without chronic complication], any cancer [any malignancy, including leukemia and lymphoma / metastatic solid tumor], moderate or severe renal disease), and concomitant medications (ie, ACE inhibitor, \(\beta\)-blocker, bronchodilator, calcium channel blocker, corticosteroid, hydroxychloroquine, azithromycin, other antibiotic medication, other anticoagulants [ie, not enoxaparin or heparin], remdesivir, other antiviral medication, tocilizumab). Discharge status was not included in the model examining in-hospital mortality. N = 122,508 inpatients for all models except total cost, where N = 104,569.

\textsuperscript{b}Estimates are the odds ratio for logistic regression models and the exponentiated coefficient for GLM. Thus, after adjusting for covariates in separate models, patients receiving therapeutic/high-dose anticoagulation had a 26\% increase in odds of in-hospital mortality and a 45\% increase in odds of ICU admission compared with patients receiving prophylactic/low-dose anticoagulation. After adjusting for covariates in separate models, average total cost per day was 28\% greater and average LOS was 21\% longer among inpatients receiving therapeutic/high-dose anticoagulation compared with inpatients receiving prophylactic/low-dose anticoagulation.
between the two groups, and patient demographics, comorbidities and severity were controlled for in regression analyses, it is possible that unknown confounding factors or unobservable clinical differences could contribute to the differences in the outcomes between the two dosage groups. Low-high classification and intent of anticoagulant dosing could not be further delineated in this analysis. Comparisons between inpatients with no prescribed anticoagulants and prophylactic/low-dose anticoagulation, or proportion of enoxaparin versus heparin within anticoagulant groups were not explored in this study. Because anticoagulant dosage was examined retrospectively, regression models controlled for critical illness overall rather than dichotomizing patients. Nonetheless, this study captured empiric anticoagulant use and outcomes during a time when clinicians had little guidance on how to treat patients with COVID-19.

This study is notable for its use of real-world data to examine anticoagulant dosage and management approaches in more than 100,000 inpatients with COVID-19. Large administrative databases facilitate the larger-scale exploration of patient care and outcomes during outbreaks of established and emerging diseases. Instituting standards of care that maximize overall patient benefits is essential, not only during pandemic peaks – which lead to high levels of treatment fatigue and have a serious impact on healthcare professional resources – but also more generally, as COVID-19 is likely to become endemic. As the course of COVID-19 in hospitalized patients has become clearer and COVID-specific treatments continue to be developed, clinicians should feel comfortable using established methods of care that include prophylactic/low-dose anticoagulant heparinoids.

Conclusion

Hospitals and patients benefit from lower HRU and costs. This study provides real-world data that in patients hospitalized with COVID-19, use of prophylactic/low-dose anticoagulation is associated with shorter LOS, lower costs, lower proportions of ICU admissions and in-hospital deaths, and better clinical outcomes compared to therapeutic/high dose after controlling for clinical differences. Higher anticoagulant use as a therapeutic intervention did not result in observed improvements in outcomes. Therefore, prophylactic/low-dose anticoagulant therapy may be appropriate for hospitalized patients with COVID-19 and warrants further investigation.

Acknowledgements

Amy Karon, DVM, MPH, senior medical writer with PINC AI™ Applied Sciences, Premier Inc., provided literature review, manuscript editing, and publication support.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by Meitheal Pharmaceuticals, Inc. Publication of study results was not contingent on the sponsor’s approval or censorship of the manuscript.

Financial Disclosures

Keith Robinson, an employee of Syneos Health, provided consulting services to Meitheal Pharmaceuticals, Inc. on this project. Tom Matthews is a former employee of Meitheal Pharmaceuticals, Inc. and a current employee of Xentria, Inc. Vivek B. Ajmani, Zhun Cao, Laura L. Schott, and Manu Tyagi are employees of Premier, Inc. which was contracted by Meitheal Pharmaceuticals, Inc. for this project. Nancy Sacco is a former employee of Meitheal Pharmaceuticals, Inc. and a current employee of SiteBridge Research, Inc., and Hexima Ltd.

Informed Consent

Informed consent for patient information published in this article was not obtained because the PHD has been certified as deidentified and is not considered human subjects research. Study data and recorded information could not be identified directly or through identifiers linked to individuals.

ORCID iD

Laura L. Schott https://orcid.org/0000-0001-8386-395X

Supplemental Material

Supplemental material for this article is available online.

References

1. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-943. doi:10.1001/jamainternmed.2020.0994.

2. Zhou X, Cheng Z, Luo L, et al. Incidence and impact of disseminated intravascular coagulation in COVID-19: a systematic review and meta-analysis. Thromb Res. 2021 May;201:23-29. doi:10.1016/j.thromres.2021.02.010.

3. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489-500. doi:10.1182/blood.2020006520.

4. Miesbach W, Makris M, COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620938149. doi:10.1177/1076029620938149.

5. Xiong X, Chi J, Gao Q. Prevalence and risk factors of thrombotic events on patients with COVID-19: a systematic review and meta-analysis. Thromb J. 2021;19(1):32. doi:10.1186/s12959-021-00284-9.

6. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. N Engl J Med. 1999;341(11):793-800. doi:10.1056/nejm199909093411103.
7. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. Br Med J. 2006;332(7537):325-329. doi:10.1136/bmj.38733.466748.7C.

8. Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS. Meta-analysis of venous thromboembolism prophylaxis in medically ill patients. Clin Ther. 2007;29(11):2395-2405. doi:10.1016/j.clinthera.2007.11.015.

9. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874-879. doi:10.1161/01.cir.0000138928.83266.24.

10. Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19. JAMA Netw Open. 2020;3(12):e2029058. doi:10.1001/jamanetworkopen.2020.29058.

11. Vaughn VM, Yost M, Abshire C, et al. Trends in venous thromboembolism anticoagulation in patients hospitalized with COVID-19. JAMA Netw Open. 2021;4(6):e2111788. doi:10.1001/jamanetworkopen.2021.11788.

12. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-1099. doi:10.1111/jth.14817.

13. Rentsch CT, Beckman JA, Tomlinson L, et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. Br Med J. 2021 Feb;372:n311. doi:10.1136/bmj.n311.

14. Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859-1865. doi:10.1111/jth.14929.

15. Thachil J, Tang N, Gando S, et al. ISTH Interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-1026. doi:10.1111/jth.14929.

16. Atlah B, Mallah SL, AlMahmeed W. Anticoagulation in COVID-19. Eur Heart J Cardiovasc Pharmacother. 2020;6(4):260-261. doi:10.1093/ehjcvp/pva036.

17. Moores LK, Trischler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020;158(3):1143-1163. doi:10.1016/j.chest.2020.05.559.

18. Coppock D, Baram M, Chang AM, et al. COVID-19 treatment combinations and associations with mortality in a large multi-site healthcare system. PLoS One. 2021;16(6):e0252591. doi:10.1371/journal.pone.0252591.

19. Paranjpe I, Fuster V, Lala A, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76(1):122-124. doi:10.1016/j.jacc.2020.05.001.

20. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(23):2950-2973. doi:10.1016/j.jacc.2020.04.031.

21. Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020 Jul;191:145-147. doi:10.1016/j.thromres.2020.04.013.

22. Lemos ACB, do Espírito Santo DA, Salvetti MC, et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID). Thromb Res. 2020 Dec;196:359-366. doi:10.1016/j.thromres.2020.09.026.

23. Meizlish ML, Goshua G, Liu Y, et al. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis. Am J Hematol. 2021;96(4):471-479. doi:10.1002/ajh.26102.

24. Jonmarker S, Hollenberg J, Dahlberg M, et al. Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients. Crit Care. 2020;24(1):653. doi:10.1186/s13054-020-03375-7.

25. Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: a systematic review and an updated meta-analysis. Semin Thromb Hemost. 2021;47(4):372-391. doi:10.1055/s-0041-1726034.

26. REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, et al. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. N Engl J Med. 2021;385(9):777-789. doi:10.1056/NEJMoa2034147.

27. ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. N Engl J Med. 2021;385(9):790-802. doi:10.1056/NEJMoa2105911.

28. Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181(12):1612-1620. doi:10.1001/jamainternmed.2021.6203.

29. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24(1):360. doi:10.1186/s13054-020-03077-0.

30. Lynn L, Reyes JA, Hawkins K, et al. The effect of anticoagulation on clinical outcomes in novel coronavirus (COVID-19) pneumonia in a U. S. Cohort. Thromb Res. 2021 Jan;197:65-68. doi:10.1016/j.thromres.2020.10.031.

31. Talasaz AH, Sadeghipour P, Kakavand H, et al. Recent randomized trials of antithrombotic therapy for patients with COVID-19: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77(15):1903-1921. doi:10.1016/j.jacc.2021.02.035.

32. Chiam T, Subedi K, Chen D, et al. Hospital length of stay among COVID-19-positive patients. J Clin Transl Res. 2021;7(3):377-385.

33. Conway RP, Byrne DG, O’Riordan DMR, et al. Emergency medical admissions and COVID-19: impact on 30-day mortality and hospital length of stay. Ir J Med Sci. 2022;191(4):1905-1911. doi:10.1007/s11845-021-02752-7.

34. Jeck J, Jakobs F, Kron A, Franz J, Cornely OA, Kron F. A cost of illness study of COVID-19 patients and retrospective modelling of
potential cost savings when administering remdesivir during the pandemic "first wave" in a German tertiary care hospital. *Infection. 2022;50(1):191-201. doi:10.1007/s15010-021-01685-8*

35. Miethke-Morais A, Cassenote A, Piva H, et al. COVID-19-related hospital cost-outcome analysis: the impact of clinical and demographic factors. *Braz J Infect Dis. 2021;25(4):101609. doi:10.1016/j.bjid.2021.101609.*

36. Moon RC, Mackey RH, Cao Z, et al. Is COVID-19 Less Deadly Now? -- Trends of In-Hospital Mortality Among Hospitalized COVID-19 Patients in the United States. *Clin Infect Dis. 2022;74(12):2238-2242. doi:10.1093/cid/cia8830.*

37. Oksuz E, Malhan S, Gonen MS, Kutlubay Z, Keskindemirci Y, Tabak F. COVID-19 healthcare cost and length of hospital stay in Turkey: retrospective analysis from the first peak of the pandemic. *Health Econ Rev. 2021;11(1):39. doi:10.1186/s13561-021-00338-8.*

38. Moon RC, Brown H, Rosenthal N. Healthcare resource utilization of patients with COVID-19 visiting US hospitals. *Value Health. 2022 May;25(5):751-760. doi:10.1016/j.jval.2021.12.005.*

39. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. *Br Med J. 2020 May;369:m1985. doi:10.1136/bmj.m1985.*

40. Guo A, Lu J, Tan H, et al. Risk factors on admission associated with hospital length of stay in patients with COVID-19: a retrospective cohort study. *Sci Rep. 2021;11(1):7310. doi:10.1038/s41598-021-86853-4.*

41. Cowper PA, Sheng S, Lopes RD, et al. Economic analysis of apixaban therapy for patients with atrial fibrillation from a US perspective: results from the ARISTOTLE randomized clinical trial. *JAMA Cardiol. 2017;2(5):525-534. doi:10.1001/jamacardio.2017.0065.*

42. Huang W, Anderson FA, Rushton-Smith SK, Cohen AT. Effect of thromboprophylaxis across the US acute care setting. *PLoS One. 2015;10(3):e0121429. doi:10.1371/journal.pone.0121429.*

43. Veeranki SP, Xiao Z, Levorsen A, Sinha M, Shah BR. Real-World comparative effectiveness and cost comparison of thromboprophylaxis in patients with COVID-19. *Blood Adv. 2021;5(3):872-888. doi:10.1182/bloodadvances.2020003763.*

44. Leykum L, Pugh J, Diuguid D, Papadopoulos K. Cost utility of substituting enoxaparin for unfractionated heparin for prophylaxis of venous thrombosis in the hospitalized medical patient. *J Hosp Med. 2006;1(3):168-176. doi:10.1002/jhm.97.*

45. Fowler RA, Mittmann N, Geerts W, et al. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. *JAMA. 2014;312(20):2135-2145. doi:10.1001/jama.2014.15101.*

46. Deitelzweig SB, Becker R, Lin J, Benner J. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism. *Thromb Haemost. 2008;100(5):810-820.*

47. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol. 1992;45(6):613-619. doi:10.1016/0895-4356(92)90133-8.*

48. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. *Am J Epidemiol. 2011;173(6):676-682. doi:10.1093/aje/kwq433.*

49. Kroch EA, Duan M. CareScience Risk Assessment Model: Hospital Performance Measurement. 2008.

50. Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. *Res Pract Thromb Haemost. 2020;4(7):1178-1191. doi:10.1002/rth2.12439.*

51. Lavery AM, Preston LE, Ko JY, et al. Characteristics of hospitalized COVID-19 patients discharged and experiencing same-hospital readmission - United States, march-August 2020. *MMWR Morb Mortal Wkly Rep. 2020;69(45):1695-1699. doi:10.15585/mmwr.mm6945e2.*

52. Billett HH, Reyes-Gil M, Szymanski J, et al. Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality. *Thromb Haemost. 2020;120(12):1691-1699. doi:10.1055/s-0040-1720978.*

53. Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of haematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. *Blood Adv. 2021;5(3):872-888. doi:10.1182/bloodadvances.2020003763.*

54. Pawlowski C, Venkatakrishnan AJ, Kirkup C, et al. Enoxaparin is associated with lower rates of mortality than unfractionated heparin in hospitalized COVID-19 patients. *EClinicalMedicine. 2021 Mar;33:100774. doi:10.1016/j.eclinm.2021.100774.*

55. Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. *J Am Coll Cardiol. 2020;76(16):1815-1826. doi:10.1016/j.jacc.2020.08.041.*

56. Anderson MR, Bach PB, Baldwin MR. Hospital length of stay for patients with severe COVID-19: implications for remdesivir’s value. *PharmacoEconomics - Open. 2021;5(1):129-131. doi:10.1007/s41669-020-00243-6.*

57. Moonla C, Sosothikul D, Chiasakul T, Rojnuckarin P, Uaprasert N. Anticoagulation and in-hospital mortality from coronavirus disease 2019: a systematic review and meta-analysis. *Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211008999. doi:10.1177/10760296211008999.*

58. Sholzberg M, Tang GH, Rahhal H, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with COVID-19 admitted to hospital: RAPID randomised clinical trial. *Br Med J. 2021 Oct 14;375:n2400. doi:10.1136/bmj.n2400.*

59. Perepu US, Chambers I, Wahab A, et al. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multi-center, open-label, randomized controlled trial. *J Thromb Haemost. 2021;19(9):2225-2234. https://doi.org/10.1111/jth.15450.*

60. Hozayen SM, Zychowski D, Benson S, et al. Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients. *EClinicalMedicine. 2021 Nov;41:101139. doi:10.1016/j.eclinm.2021.101139.*

61. Gülci O, Aksakal E, Aydemir S, et al. Association between previous anticoagulant use and mortality among hospitalized patients
with COVID-19. *J Thromb Thrombolysis*. 2022;53(1):88–95. doi:10.1007/s11239-021-02489-1

62. Giannis D, Allen SL, Tsang J, et al. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. *Blood*. 2021;137(20):2838-2847. doi:10.1182/blood.2020010529.

63. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. *Sci Rep*. 2021;11(1):16144. doi:10.1038/s41598-021-95565-8.

64. Morin L, Savale L, Pham T, et al. Four-Month clinical Status of a cohort of patients after hospitalization for COVID-19. *JAMA*. 2021;325(15):1525-1534. doi:10.1001/jama.2021.3331.

65. Salah HM, Naser JA, Calcaterra G, Bassareo PP, Mehta JL. The effect of anticoagulation use on mortality in COVID-19 infection. *Am J Cardiol*. 2020 Nov;134:155-157. doi:10.1016/j.amjcard.2020.08.005.

66. Cryer MJ, Farhan S, Kaufmann CC, et al. Prothrombotic milieu, thrombotic events and prophylactic anticoagulation in hospitalized COVID-19 positive patients: a review. *Clin Appl Thromb Hemost*. 2022 Jan-Dec;28:10760296221074353. doi:10.1177/10760296221074353.

67. Liu H, Wang Z, Sun H, et al. Thrombosis and coagulopathy in COVID-19: current understanding and implications for antithrombotic treatment in patients treated with percutaneous coronary intervention. *Front Cardiovasc Med*. 2021 Jan;7:599334. doi:10.3389/fcvm.2020.599334.

68. Kasinathan G, Sathar J. Haematological manifestations, mechanisms of thrombosis and anti-coagulation in COVID-19 disease: a review. *Ann Med Surg (Lond)*. 2020 Jun;56:173-177. doi:10.1016/j.aimsu.2020.06.035.

69. Zhang S, Liu Y, Wang X, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. *J Hematol Oncol*. 2020;13(1):120. doi:10.1186/s13045-020-00954-7.

70. Fajgenbaum DC, June CH. Cytokine storm. *N Engl J Med*. 2020;383(23):2255-2273. doi:10.1056/NEJMra2026131.

71. Rico-Mesa JS, Rosas D, Ahmadian-Tehrani A, White A, Anderson AS, Chilton R. The role of anticoagulation in COVID-19-induced hypercoagulability. *Curr Cardiol Rep*. 2020;22(7):53. doi:10.1007/s11886-020-01328-8.

72. Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalized patients with COVID-19 in a New York city health system. *JAMA*. 2020;324(8):799-801. doi:10.1001/jama.2020.13372.

73. Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. *J Thromb Haemost*. 2020;18(8):1995-2002. doi:10.1111/jth.14888.